NCT00026624View on ClinicalTrials.gov

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Study Completion Date

October 31, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

DRUG

Keyhole-Limpet Hemocyanin

Trial Locations (2)

10003

Beth Israel Med. Ctr., ACTU, New York

02114

Massachusetts General Hospital ACTG CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00026624 - Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC | Biotech Hunter | Biotech Hunter